Approval · Notice of Compliance 13005 · 2012
LOVENOX: Notice of Compliance 13005
Issued February 3, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13005
- Date
- February 3, 2012
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Admin
- Reason
- For issuance of DINS for Unit Dose pre-filled syringes
- Therapeutic class
- Anticoagulant - Antithrombotic Agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LOVENOX | 02012472 | Marketed |
| LOVENOX | 02236883 | Marketed |
| LOVENOX | 02378426 | Marketed |
| LOVENOX | 02378434 | Marketed |
| LOVENOX | 02378442 | Marketed |
| LOVENOX HP | 02242692 | Marketed |
| LOVENOX HP | 02378450 | Cancelled Pre Market |
| LOVENOX HP | 02378469 | Marketed |
Medicinal ingredients
- ENOXAPARIN SODIUM 30 MG per 0.3ML
- ENOXAPARIN SODIUM 40 MG per 0.4ML
- ENOXAPARIN SODIUM 60 MG per 0.6ML
- ENOXAPARIN SODIUM 80 MG per 0.8ML
- ENOXAPARIN SODIUM 100 MG per ML
- ENOXAPARIN SODIUM 120 MG per 0.8ML
- ENOXAPARIN SODIUM 90 MG per 0.6ML
- ENOXAPARIN SODIUM 150 MG per ML